Innovent Biologics Statistics
Share Statistics
Innovent Biologics has 1.65B
shares outstanding. The number of shares has increased by 0.62%
in one year.
| Shares Outstanding | 1.65B |
| Shares Change (YoY) | 0.62% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 5.96M, so 0% of the outstanding
shares have been sold short.
| Short Interest | 5.96M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 999.99 |
Valuation Ratios
The PE ratio is -547.41 and the forward
PE ratio is 9.31.
Innovent Biologics's PEG ratio is
6.
| PE Ratio | -547.41 |
| Forward PE | 9.31 |
| PS Ratio | 5.5 |
| Forward PS | 0.4 |
| PB Ratio | 3.95 |
| P/FCF Ratio | 0 |
| PEG Ratio | 6 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Innovent Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35,
with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.35 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | -5.89 |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,664,938.68 |
| Profits Per Employee | $-16,722.21 |
| Employee Count | 5,659 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | 16.01M |
| Effective Tax Rate | -20.36% |
Stock Price Statistics
The stock price has increased by 60.65% in the
last 52 weeks. The beta is 0.28, so Innovent Biologics's
price volatility has been higher than the market average.
| Beta | 0.28 |
| 52-Week Price Change | 60.65% |
| 50-Day Moving Average | 6.02 |
| 200-Day Moving Average | 5.27 |
| Relative Strength Index (RSI) | 71.92 |
| Average Volume (20 Days) | 4,228 |
Income Statement
In the last 12 months, Innovent Biologics had revenue of 9.42B
and earned -94.63M
in profits. Earnings per share was -0.06.
| Revenue | 9.42B |
| Gross Profit | 7.91B |
| Operating Income | -755.87M |
| Net Income | -94.63M |
| EBITDA | -480.28M |
| EBIT | -755.87M |
| Earnings Per Share (EPS) | -0.06 |
Full Income StatementBalance Sheet
The company has 7.51B in cash and 2.83B in
debt, giving a net cash position of 4.68B.
| Cash & Cash Equivalents | 7.51B |
| Total Debt | 2.83B |
| Net Cash | 4.68B |
| Retained Earnings | n/a |
| Total Assets | 21.6B |
| Working Capital | 5.9B |
Full Balance SheetMargins
Gross margin is 83.97%, with operating and profit margins of -8.02% and -1%.
| Gross Margin | 83.97% |
| Operating Margin | -8.02% |
| Pretax Margin | -0.83% |
| Profit Margin | -1% |
| EBITDA Margin | -5.1% |
| EBIT Margin | -8.02% |
| FCF Margin | n/a |
